Retatrutide CAS 2381089-83-2

5/10/15mg

Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through subcutaneous and intravenous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.